GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Instem PLC (LSE:INS) » Definitions » Capex-to-Revenue

Instem (LSE:INS) Capex-to-Revenue : 0.07 (As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Instem Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Instem's Capital Expenditure for the six months ended in Jun. 2023 was £-1.95 Mil. Its Revenue for the six months ended in Jun. 2023 was £29.74 Mil.

Hence, Instem's Capex-to-Revenue for the six months ended in Jun. 2023 was 0.07.


Instem Capex-to-Revenue Historical Data

The historical data trend for Instem's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instem Capex-to-Revenue Chart

Instem Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.06 0.05 0.05 0.06

Instem Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.06 0.06 0.07

Competitive Comparison of Instem's Capex-to-Revenue

For the Health Information Services subindustry, Instem's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instem's Capex-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Instem's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Instem's Capex-to-Revenue falls into.



Instem Capex-to-Revenue Calculation

Instem's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-3.514) / 58.88
=0.06

Instem's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1.947) / 29.742
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Instem  (LSE:INS) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Instem Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Instem's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Instem (LSE:INS) Business Description

Traded in Other Exchanges
N/A
Address
Diamond Way, Stone Business Park, Stone, Staffordshire, GBR, ST15 0SD
Instem PLC acts as a supplier of IT applications and technology-enabled outsourced services to the global health and life sciences community. Its segments include Study Management, Regulatory Solutions, and In Silico Solutions, Clinical Trial Acceleration. The company generates maximum revenue from Study Management. Geographically, it derives a majority of its revenue from the United States and also has a presence in the Europe and Rest of the World. Its portfolio of software solutions includes Instem Cloud, SEND Data Conversion, KnowledgeScan, SENDReady Consulting, Solution Deployment, Validation, Data Management, and Regulatory Information Management.

Instem (LSE:INS) Headlines

No Headlines